Evidence map›Paper›PMID 32107737›Full record

ReviewOphthalmology and therapy2020

Umbilical Cord Blood and Serum for the Treatment of Ocular Diseases: A Comprehensive Review.

Giuseppe Giannaccare, Adriano Carnevali, Carlotta Senni, Laura Logozzo, Vincenzo Scorcia

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Ophthalmology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Autologous blood in the management of ocular surface disorders.World journal of experimental medicine · 2024
    Review
  11. Article
  12. Article
  13. Mitochondria Transplantation Promotes Corneal Epithelial Wound Healing.Investigative ophthalmology & visual science · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Safety and efficacy of eye drops from umbilical cord blood platelet lysate to treat resistant corneal ulcer.Medical hypothesis, discovery & innovation ophthalmology journal · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Giuseppe GiannaccareDepartment of Ophthalmology, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Adriano CarnevaliDepartment of Ophthalmology, University Magna Graecia of Catanzaro, Catanzaro, Italy. adrianocarnevali@live.it.
Carlotta SenniOphthalmology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy.
Laura LogozzoDepartment of Ophthalmology, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Vincenzo ScorciaDepartment of Ophthalmology, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Magna Graecia University · ITPoliclinico S.Orsola-Malpighi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several blood derivatives have been proposed for the treatment of various ocular diseases that affect either the anterior or the posterior segment of the eye. Blood sources may range from the patient's own peripheral blood (autologous) to donor tissues, mainly allogeneic peripheral blood and umbilical cord blood (UCB). The utilization of the latter permits the collection of a large amount of serum all at once, and is characterized by therapeutic feasibility in patients with a poor general condition or anemia and blood dyscrasia. Products derived from UCB have two potential uses. First, serum in the form of eye drops can be applied topically onto the ocular surface to efficiently treat anterior segment disorders such as dry eye syndrome or corneal epithelial defects with different etiologies. The rationale for and efficacy of this application derive from the high concentrations of biologically active components and growth factors in UCB, which can nourish the ocular surface. Second, UCB is a source of stem cells, which are used in the field of regenerative medicine because they differentiate into various mature cells, including corneal and retinal cells. Therefore, UCB-derived stem cells have been proposed as a replacement therapy for the treatment of retinal and optic nerve diseases, given that current standard treatments often fail. The present review explores the clinical results that have been obtained using UCB-derived products in the field of ophthalmology, as well as the current limitations of those products in this field. Furthermore, given the promising development of UCB-based therapies, possible future directions in this area are discussed.

Indexed as

Allogeneic serumCorneaOcular surface diseaseOptic nerveRetinaStem cellsUmbilical cord bloodUmbilical cord blood serum

Identifiers

PMID32107737
PMCPMC7196109
OpenAlexW3007664018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.